Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway

Molecular and Cellular Biology

Volumn 24, Issue 19, 2004, Pages 8681-8690

  Guo, Shangqin ^a   Sonenshein, Gail E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; WORTMANNIN;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; ENZYME INACTIVATION; ESTROGEN ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE OVEREXPRESSION; GENE TARGETING; GENETIC LINKAGE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HETEROZYGOSITY LOSS; HORMONAL REGULATION; IMMUNOPRECIPITATION; MOUSE; MYRISTYLATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR INTRINSIC ACTIVITY; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BINDING SITES; ESTROGEN RECEPTOR ALPHA; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; MICE; PROMOTER REGIONS (GENETICS); PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 4544369383     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.19.8681-8690.2004     Document Type: Article

References (78)

1. Biswas, D. K., A. P. Cruz, E. Gansberger, and A. B. Pardee. 2000. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA 97:8542-8547.
2. Bois, P. R., and G. C. Grosveld. 2003. FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts. EMBO J. 22:1147-1157.
3. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis, and M. E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868.
4. Brunet, A., G. Pages, and J. Pouyssegur. 1994. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 9:3379-3387.
5. Burgess, A. W., H. S. Cho, C. Eigenbrot, K. M. Ferguson, T. P. Garrett, D. J. Leahy, M. A. Lemmon, M. X. Sliwkowski, C. W. Ward, and S. Yokoyama. 2003. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12:541-552.
6. Campbell, R. A., P. Bhat-Naksbatri, N. M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri. 2001. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276:9817-9824.
7. Chrysogelos, S. A., and R. B. Dickson. 1994. EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res. Treat. 29:29-40.
8. Clark, A. S., K. West, S. Streicher, and P. A. Dennis. 2002. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1:707-717.
9. Clarke, R. B., A. Howell, C. S. Potten, and E. Anderson. 1997. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 57:4987-4991.
10. Couse, J. F., and K. S. Korach. 1999. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20:358-417.
11. Darcy, K. M., D. Zangani, A. L. Wohlhueter, R. Y. Huang, M. M. Vaughan, J. A. Russell, and M. M. Ip. 2000. Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells. J. Histochem. Cytochem. 48:63-80.
12. deConinck, E. C., L. A. McPherson, and R. J. Weigel. 1995. Transcriptional regulation of estrogen receptor in breast carcinomas. Mol. Cell. Biol. 15: 2191-2196.
13. Di Fiore, P. P., J. H. Pierce, M. H. Kraus, O. Segatto, C. R. King, and S. A. Aaronson. 1987. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182.
14. Dowsett, M. 2001. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer 8:191-195.
15. Duyao, M. P., A. J. Buckler, and G. E. Sonenshein. 1990. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc. Natl. Acad. Sci. USA 87:4727-4731.
16. Eccles, S. A. 2001. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J. Mammary Gland Biol. Neoplasia 6:393-406.
17. Elson, A., and P. Leder. 1995. Protein-tyrosine phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras or neu. J. Biol. Chem. 270:26116-26122.
18. Farmer, S. R. 2003. The forkhead transcription factor Foxol: a possible link between obesity and insulin resistance. Mol. Cell 11:6-8.
19. Finlin, B. S., C. L. Gau, G. A. Murphy, H. Shao, T. Kimel, R. S. Seitz, Y. F. Chiu, D. Botstein, P. O. Brown, C. J. Der, F. Tamanoi, D. A. Andres, and C. M. Perou. 2001. RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. J. Biol. Chem. 276:42259-42267.
20. Fujita, N., D. L. Jaye, M. Kajita, C. Geigerman, C. S. Moreno, and P. A. Wade. 2003. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113:207-219.
21. Gee, J. M., M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling, and R. I. Nicholson. 2003. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144:5105-5117.
22. Grant, S., L. Qiao, and P. Dent. 2002. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 7:d376-d389.
23. Hatta, M., H. Daitoku, H. Matsuzaki, Y. Deyama, Y. Yoshimura, K. Suzuki, A. Matsumoto, and A. Fukamizu. 2002. Regulation of alkaline phosphatase promoter activity by forkhead transcription factor FKHR. Int. J. Mol. Med. 9:147-152.
24. Hortobagyi, G. N., M. C. Hung, and A. U. Buzdar. 1999. Recent developments in breast cancer therapy. Semin. Oncol. 26:11-20.
25. Hsu, A. L., T. T. Ching, D. S. Wang, X. Song, V. M. Rangnekar, and C. S. Chen. 2000. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275:11397-11403.
26. Hudziak, R. M., J. Schlessinger, and A. Ullrich. 1987. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 84:7159-7163.
27. Iwase, H., Y. Omoto, H. Iwata, T. Toyama, Y. Hara, Y. Ando, Y. Ito, Y. Fujii, and S. Kobayashi. 1999. DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. Br. J. Cancer 80:1982-1986.
28. Jackson, J. G., J. I. Kreisberg, A. P. Koterba, D. Yee, and M. G. Brattain. 2000. Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene 19:4574-4581.
29. Jeay, S., S. Pianetti, H. M. Kagan, and G. E. Sonenshein. 2003. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol. Cell. Biol. 23:2251-2263.
30. L promoter activity by NF-kappa B family members. J. Virol. 76:5737-5747.
31. Keen, J. C., and N. E. Davidson. 2003. The biology of breast carcinoma. Cancer 97:825-833.
32. Kurokawa, H., and C. L. Arteaga. 2003. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin. Cancer Res. 9:511S-515S.
33. La Rosa, F. A., J. W. Pierce, and G. E. Sonenshein. 1994. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol. Cell. Biol. 14:1039-1044.
34. Lawlor, M. A., and D. R. Alessi. 2001. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci. 114:2903-2910.
35. Lazar, H., A. Baltzer, C. Gimmi, A. Marti, and R. Jaggi. 2000. Over-expression of erbB-2/neu is paralleled by inhibition of mouse-mammary-epithelial-cell differentiation and developmental apoptosis. Int. J. Cancer 85:578-583.
36. Lee, C. S., A. deFazio, C. J. Ormandy, and R. L. Sutherland. 1996. Inverse regulation of oestrogen receptor and epidermal growth factor receptor gene expression in MCF-7 breast cancer cells treated with phorbol ester. J. Steroid Biochem. Mol. Biol. 58:267-275.
37. Leenders, H., S. Whiffield, C. Benoist, and D. Mathis. 2000. Role of the forkhead transcription family member, FKHR, in thymocyte differentiation. Eur. J. Immunol. 30:2980-2990.
38. Liu, Y., D. el-Ashry, D. Chen, I. Y. Ding, and F. G. Kern. 1995. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res. Treat. 34:97-117.
39. Lu, J., M. J. Pazin, and K. Ravid. 2004. Properties of ets-1 binding to chromatin and its effect on platelet factor 4 gene expression. Mol. Cell. Biol. 24:428-441.
40. McCarthy, K. M., D. McDevit, A. Andreucci, R. Reeves, and B. S. Nikolajczyk. 2003. HMGA1 co-activates transcription in B cells through indirect association with DNA. J. Biol. Chem. 278:42106-42114.
41. McCarty, K. S., Jr., T. K. Barton, B. F. Fetter, B. H. Woodard, J. A. Mossler, W. Reeves, J. Daly, W. E. Wilkinson, and K. S. McCarty, Sr. 1980. Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma. Cancer 46:2851-2858.
42. McClelland, R. A., D. Barrow, T. A. Madden, C. M. Dutkowski, J. Pamment, J. M. Knowlden, J. M. Gee, and R. I. Nicholson. 2001. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142:2776-2788.
43. Medema, R. H., G. J. Kops, J. L. Bos, and B. M. Burgering. 2000. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404:782-787.
44. Mossler, J. A., K. S. McCarty, Jr., and W. W. Johnston. 1981. The correlation of cytologic grade and steroid receptor content in effusions of metastatic breast carcinoma. Acta Cytol. 25:653-658.
45. Nakachi, K., K. Suemasu, K. Suga, T. Takeo, K. Imai, and Y. Higashi. 1998. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn. J. Cancer Res. 89:254-261.
46. Nakamura, N., S. Ramaswamy, F. Vazquez, S. Signoretti, M. Loda, and W. R. Sellers. 2000. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol. 20: 8969-8982.
47. Nicholson, R. I., I. R. Hutcheson, M. E. Harper, J. M. Knowlden, D. Barrow, R. A. McClelland, H. E. Jones, A. E. Wakeling, and J. M. Gee. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr. Relat. Cancer 8:175-182.
48. Oh, A. S., L. A. Lorant, J. N. Holloway, D. L. Miller, F. G. Kern, and D. El-Ashry. 2001. Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol. Endocrinol. 15:1344-1359.
49. Osborne, C. K. 1998. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 51:227-238.
50. Pages, G., A. Brunet, G. L'Allemain, and J. Pouyssegur. 1994. Constitutive mutant and putative regulatory serine phosphorylation site of mammalian MAP kinase kinase (MEK1). EMBO J. 13:3003-3010.
51. Park, W. C., and V. C. Jordan. 2002. Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention. Trends Mol. Med. 8:82-88.
52. Perou, C. M., T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale, P. O. Brown, and D. Botstein. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
53. Pianetti, S., M. Arsura, R. Romieu-Mourez, R. J. Coffey, and G. E. Sonenshein. 2001. Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-α that can be inhibited by the tumor suppressor PTEN. Oncogene 20:1287-1299.
54. Pianetti, S., S. Guo, K. T. Kavanagh, and G. E. Sonenshein. 2002. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 62: 652-655.
55. Pietras, R. J., J. Arboleda, D. M. Reese, N. Wongvipat, M. D. Pegram, L. Ramos, C. M. Gorman, M. G. Parker, M. X. Sliwkowski, and D. J. Slamon. 1995. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446.
56. Rishi, A. K., Z. M. Shao, R. G. Baumann, X. S. Li, M. S. Sheikh, S. Kimura, N. Bashirelahi, and J. A. Fontana. 1995. Estradiol regulation of the human retinoic acid receptor alpha gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs. Cancer Res. 55:4999-5006.
57. Rodriguez, C., A. Causse, E. Ursule, and C. Theillet. 2000. At least five regions of imbalance on 6q in breast tumors, combining losses and gains. Genes Chromosomes Cancer 27:76-84.
58. Russo, J., X. Ao, C. Grill, and I. H. Russo. 1999. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat. 53:217-227.
59. Saceda, M., T. W. Grunt, R. Colomer, M. E. Lippman, R. Lupu, and M. B. Martin. 1996. Regulation of estrogen receptor concentration and activity by an ErbB/HER ligand in breast carcinoma cell lines. Endocrinology 137: 4322-4330.
60. Saji, S., E. V. Jensen, S. Nilsson, T. Rylander, M. Warner, and J. A. Gustafsson. 2000. Estrogen receptors alpha and beta in the rodent mammary gland. Proc. Natl. Acad. Sci. USA 97:337-342.
61. Samatar, A. A., L. Wang, A. Mirza, S. Koseoglu, S. Liu, and C. C. Kumar. 2002. Transforming growth factor-beta 2 is a transcriptional target for Akt/protein kinase B via forkhead transcription factor. J. Biol. Chem. 277:28118-28126.
62. Schiff, R., S. Massarweh, J. Shou, and C. K. Osborne. 2003. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 9:447S-454S.
63. Schuur, E. R., A. V. Loktev, M. Sharma, Z. Sun, R. A. Roth, and R. J. Weigel. 2001. Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. J. Biol. Chem. 276:33554-33560.
64. Skurk, C., H. Maatz, H. S. Kim, J. Yang, M. R. Abid, W. C. Aird, and K. Walsh. 2004. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J. Biol. Chem. 279:1513-1525.
65. Stern, D. F. 2003. ErbBs in mammary development. Exp. Cell Res. 284:89-98.
66. Stern, D. F. 2000. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2:176-183.
67. Subbaramaiah, K., and A. J. Dannenberg. 2003. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24:96-102.
68. Suhara, T., H. S. Kim, L. A. Kirshenbaum, and K. Walsh. 2002. Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol. Cell. Biol. 22:680-691.
69. Tagliabue, E., S. Menard, J. F. Robertson, and L. Harris. 1999. c-erbB-2 expression in primary breast cancer. Int. J. Biol. Markers 14:16-26.
70. Tang, Z., I. Treilleux, and M. Brown. 1997. A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers. Mol. Cell. Biol. 17:1274-1280.
71. Tanimoto, K., H. Eguchi, T. Yoshida, K. Hajiro-Nakanishi, and S. Hayashi. 1999. Regulation of estrogen receptor alpha gene mediated by promoter B responsible for its enhanced expression in human breast cancer. Nucleic Acids Res. 27:903-909.
72. Tsai, E. M., S. C. Wang, J. N. Lee, and M. C. Hung. 2001. Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res. 61: 8390-8392.
73. Witters, L. M., R. Kumar, V. M. Chinchilli, and A. Lipton. 1997. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res. Treat. 42:1-5.
74. Wong, C. W., C. McNally, E. Nickbarg, B. S. Komm, and B. J. Cheskis. 2002. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc. Natl. Acad. Sci. USA 99:14783-14788.
75. Yang, X., D. L. Phillips, A. T. Ferguson, W. G. Nelson, J. G. Herman, and N. E. Davidson. 2001. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 61:7025-7029.
76. Yoshida, T., H. Eguchi, K. Nakachi, K. Tanimoto, Y. Higashi, K. Suemasu, Y. Iino, Y. Morishita, and S. Hayashi. 2000. Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis 21: 2193-2201.
77. Yu, X., R. V. Rajala, J. F. McGinnis, F. Li, R. E. Anderson, X. Yan, S. Li, R. V. Elias, R. R. Knapp, and W. Cao. 2004. Involvement of insulin/phosphoinositide 3-kinase/Akt signal pathway in 17β-estradiol- mediated neuroprotection. J. Biol. Chem. 279:13086-13094.
78. Zhao, H. H., R. E. Herrera, E. Coronado-Heinsohn, M. C. Yang, J. H. Ludes-Meyers, K. J. Seybold-Tilson, Z. Nawaz, D. Yee, F. G. Barr, S. G. Diab, P. H. Brown, S. A. Fuqua, and C. K. Osborne. 2001. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J. Biol. Chem. 276:27907-27912.